A Phase 2 interventional study of MK0928, gaboxadol / Duration of Treatment 3 Weeks and Placebo / Duration of Treatment 3 Weeks in Primary Insomnia, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2015-01-14.
Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.
This study's enrollment of 520 is above the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Browse Sleep Initiation and Maintenance Disorders studies →H. Lundbeck A/S is the lead sponsor of 218 studies on the registry; 10 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patient-reported total sleep time.
Patient-reported time to sleep onset, number of awakenings, wake time after sleep onset and premature awakening.
No study locations are listed for this record.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders→
H. Lundbeck A/S